Journal ad claim that oral contraceptive shows "no significant weight gain" is not supported by adequate and well-controlled clinical trials, Division of Drug Marketing, Advertising & Communications states in April 16 letter. Two multi-center six-month studies cited to support claim are inadequate because weight gain or loss was not a prospectively defined endpoint, ad division says. The ad, which appeared in March and April issues of nine professional journals, has been pulled, Pfizer said. Pfizer's Estrostep NDA for treatment of moderate acne has been pending at FDA since April 2000
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth